CliffBio
small molecule

SANDIMMUNE

CYCLOSPORINE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameSANDIMMUNE
Active ingredientCYCLOSPORINE
Strength50MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 1992
Marketing statusRX

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.